Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Eur Arch Otorhinolaryngol ; 278(11): 4321-4328, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33661356

ABSTRACT

PURPOSE: Hereditary hemorrhagic telangiectasia (HHT) is a vascular disorder that presents with recurrent, intractable epistaxis. The aim of this study was to retrospectively analyze the efficacy of various treatment options for epistaxis in patients with HHT, over a period of 18 years, and to correlate these findings with available evidence in the literature. METHODS: Records of patients with HHT, treated for epistaxis between 2000 and 2018 were analyzed. Treatment procedures carried out and their efficacy were extracted and analyzed. RESULTS: Forty-three records were evaluated. All patients were given nasal humidifying ointments, 93% required acute treatment with bipolar electrocautery, and 60% underwent atraumatic nasal packing. Recurrent cases were treated medically with tranexamic acid (26%), oestrogen (19%), and bevacizumab (2%). Laser photocoagulation was done in selected cases (40%) and if unsuccessful, septal dermoplasty was performed (2.3%). Endovascular embolization was reserved for life-threatening emergencies (7%). CONCLUSION: Epistaxis in HHT is not curable, but can be managed by employing a comprehensive stepwise approach. An algorithm for effective and comprehensive management has been presented.


Subject(s)
Epistaxis , Telangiectasia, Hereditary Hemorrhagic , Bevacizumab , Epistaxis/surgery , Epistaxis/therapy , Humans , Light Coagulation , Retrospective Studies , Telangiectasia, Hereditary Hemorrhagic/complications , Telangiectasia, Hereditary Hemorrhagic/therapy
2.
J Thromb Haemost ; 15(11): 2165-2175, 2017 11.
Article in English | MEDLINE | ID: mdl-28834238

ABSTRACT

Essentials The long-term effects of VKORC1 and CYP2C9 variants on clinical outcomes remains unclear. We followed 774 patients ≥65 years with venous thromboembolism for a median duration of 30 months. Patients with CYP2C9 variants are at increased risk of death and non-major bleeding. Patients with genetic variants have a slightly lower anticoagulation quality only. SUMMARY: Background The long-term effect of polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes remains unclear. Objectives We examined the association between CYP2C9/VKORC1 variants and long-term clinical outcomes in a prospective cohort study of elderly patients treated with vitamin K antagonists for venous thromboembolism (VTE). Methods We followed 774 consecutive patients aged ≥ 65 years with acute VTE from nine Swiss hospitals for a median duration of 30 months. The median duration of initial anticoagulant treatment was 9.4 months. The primary outcome was the time to any clinical event (i.e. the composite endpoint of overall mortality, major and non-major bleeding, and recurrent VTE. Results Overall, 604 (78%) patients had a CYP2C9 or VKORC1 variant. Three hundred and thirty-four patients (43.2%) had any clinical event, 119 (15.4%) died, 100 (12.9%) had major and 167 (21.6%) non-major bleeding, and 100 had (12.9%) recurrent VTE. After adjustment, CYP2C9 (but not VKORC1) variants were associated with any clinical event (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.08-1.66), death (HR, 1.74; 95% CI, 1.19-2.52) and clinically relevant non-major bleeding (sub-hazard ratio [SHR], 1.39; 95% CI, 1.02-1.89), but not with major bleeding (SHR, 1.03; 95% CI, 0.69-1.55) or recurrent VTE (SHR, 0.95; 95% CI, 0.62-1.44). Patients with genetic variants had a slightly lower anticoagulation quality. Conclusions CYP2C9 was associated with long-term overall mortality and non-major bleeding. Although genetic variants were associated with a slightly lower anticoagulation quality, there was no relationship between genetic variants and major bleeding or VTE recurrence.


Subject(s)
Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Cytochrome P-450 CYP2C9/genetics , Pharmacogenomic Variants , Venous Thromboembolism/drug therapy , Vitamin K Epoxide Reductases/genetics , Vitamin K/antagonists & inhibitors , Age Factors , Aged , Anticoagulants/adverse effects , Cytochrome P-450 CYP2C9/metabolism , Female , Hemorrhage/chemically induced , Humans , Male , Pharmacogenetics , Prospective Studies , Recurrence , Risk Factors , Switzerland , Time Factors , Treatment Outcome , Venous Thromboembolism/blood , Venous Thromboembolism/genetics , Venous Thromboembolism/mortality , Vitamin K Epoxide Reductases/metabolism
3.
J Thromb Haemost ; 15(8): 1576-1583, 2017 08.
Article in English | MEDLINE | ID: mdl-28574652

ABSTRACT

Essentials Accurate determination of anticoagulant plasma concentration is important in clinical practice. We studied the accuracy and consistency of anti-Xa assays for rivaroxaban in a multicentre study. In a range between 50 and 200 µg L-1 , anti-Xa activity correlated well with plasma concentrations. The clinical value might be limited by overestimation and intra- and inter-individual variation. SUMMARY: Background Determining the plasma level of direct oral anticoagulants reliably is important in the work-up of complex clinical situations. Objectives To study the accuracy and consistency of anti-Xa assays for rivaroxaban plasma concentration in a prospective, multicenter evaluation study employing different reagents and analytical platforms. Methods Rivaroxaban 20 mg was administered once daily to 20 healthy volunteers and blood samples were taken at peak and trough levels (clinicaltrials.gov NCT01710267). Anti-Xa activity was determined in 10 major laboratories using different reagents and analyzers; corresponding rivaroxaban plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS). Findings Overall Pearson's correlation coefficient of anti-Xa levels and HPLC-MS results was 0.99 for Biophen® Heparin (95% CI, 0.99, 0.99), Biophen® DiXaI (95% CI, 0.99, 0.99) and STA® anti-Xa liquid (95% CI, 0.99, 1.00). Correlation was lower in rivaroxaban concentrations below 50 µg L-1 and above 200 µg L-1 . The overall bias of the Bland-Altman difference plot was 14.7 µg L-1 for Biophen Heparin, 17.9 µg L-1 for Biophen DiXal and 19.0 µg L-1 for STA anti-Xa liquid. Agreement between laboratories was high at peak level but limited at trough level. Conclusions Anti-Xa activity correlated well with rivaroxaban plasma concentrations, especially in a range between 50 and 200 µg L-1 . However, anti-Xa assays systematically overestimated rivaroxaban concentration as compared with HPLC-MS, particularly at higher concentrations. This overestimation, coupled with an apparent interindividual variation, might affect the interpretation of results in some situations.


Subject(s)
Blood Coagulation/drug effects , Drug Monitoring/methods , Factor Xa Inhibitors/blood , Factor Xa/metabolism , Rivaroxaban/blood , Administration, Oral , Adolescent , Adult , Aged , Chromatography, High Pressure Liquid , Factor Xa Inhibitors/administration & dosage , Healthy Volunteers , Humans , Laboratory Proficiency Testing , Male , Middle Aged , Observer Variation , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Rivaroxaban/administration & dosage , Switzerland , Tandem Mass Spectrometry , Young Adult
4.
J Thromb Haemost ; 14(4): 685-94, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26816339

ABSTRACT

BACKGROUND: Venous thromboembolism (VTE) and subclinical thyroid dysfunction (SCTD) are both common in elderly patients. SCTD has been related to a hypercoagulable state and an increased thromboembolic risk. However, prospective data on the relationship between SCTD and VTE are lacking. OBJECTIVES: To investigate the relationship between SCTD and recurrent VTE (rVTE), all-cause mortality, and thrombophilic biomarkers. Patients Elderly patients with VTE were studied. METHODS: In a prospective multicenter cohort, thyroid hormones and thrombophilic biomarkers were measured 1 year after acute VTE, as both may be influenced by acute thrombosis. We defined subclinical hypothyroidism (SHypo) as elevated thyroid-stimulating hormone (TSH) levels (4.50-19.99 mIU L(-1) ), and subclinical hyperthyroidism (SHyper) as TSH levels of < 0.45 mIU L(-1) , both with normal free thyroxine levels. Outcomes were incidence of rVTE and overall mortality during follow-up starting after the 1-year blood sampling. RESULTS: Of 561 participants (58% with anticoagulation), 6% had SHypo and 5% had SHyper. After 20.8 months of mean follow-up, 9% developed rVTE and 10% died. The rVTE incidence rate was 7.2 (95% confidence interval [CI] 2.7-19.2) per 100 patient-years in SHypo participants, 0.0 (95% CI 0.0-7.6) in SHyper participants, and 5.9 (95% CI 4.4-7.8) in euthyroid participants. In multivariate analyses, the sub-hazard ratio for rVTE was 0.00 (95% CI 0.00-0.58) in SHyper participants and 1.50 (95% CI 0.52-4.34) in SHypo participants as compared with euthyroid participants, without increased levels of thrombophilic biomarkers. SHyper (hazard ratio [HR] 0.80, 95% CI 0.23-2.81) and SHypo (HR 0.99, 95% CI 0.30-3.29) were not associated with mortality. CONCLUSION: In elderly patients, SHyper may be associated with lower rVTE risks. SHypo showed a non-statistically significant pattern of an association with rVTE, without increased mortality or differences in thrombophilic biomarkers.


Subject(s)
Thyroid Diseases/complications , Thyroid Diseases/physiopathology , Venous Thromboembolism/complications , Venous Thromboembolism/physiopathology , Aged , Aged, 80 and over , Biomarkers/blood , Blood Coagulation , Female , Humans , Hyperthyroidism/physiopathology , Hypothyroidism/physiopathology , Male , Middle Aged , Prospective Studies , Risk Factors , Thromboembolism , Thrombophilia/blood , Thrombosis/physiopathology , Thyroid Diseases/mortality , Thyroid Gland/physiopathology , Thyrotropin/blood , Thyroxine/blood , Treatment Outcome , Venous Thromboembolism/mortality
5.
J Thromb Haemost ; 13(2): 197-205, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25403550

ABSTRACT

BACKGROUND: Although the possibility of bleeding during anticoagulant treatment may limit patients from taking part in physical activity, the association between physical activity and anticoagulation-related bleeding is uncertain. OBJECTIVES: To determine whether physical activity is associated with bleeding in elderly patients taking anticoagulants. PATIENTS/METHODS: In a prospective multicenter cohort study of 988 patients aged ≥ 65 years receiving anticoagulants for venous thromboembolism, we assessed patients' self-reported physical activity level. The primary outcome was the time to a first major bleeding, defined as fatal bleeding, symptomatic bleeding in a critical site, or bleeding causing a fall in hemoglobin or leading to transfusions. The secondary outcome was the time to a first clinically relevant non-major bleeding. We examined the association between physical activity level and time to a first bleeding by using competing risk regression, accounting for death as a competing event. We adjusted for known bleeding risk factors and anticoagulation as a time-varying covariate. RESULTS: During a mean follow-up of 22 months, patients with a low, moderate, and high physical activity level had an incidence of major bleeding of 11.6, 6.3, and 3.1 events per 100 patient-years and an incidence of clinically relevant non-major bleeding of 14.0, 10.3, and 7.7 events per 100 patient-years, respectively. A high physical activity level was significantly associated with a lower risk of major bleeding (adjusted sub-hazard ratio 0.40, 95% confidence interval 0.22-0.72). There was no association between physical activity and non-major bleeding. CONCLUSIONS: A high level of physical activity is associated with a decreased risk of major bleeding in elderly patients receiving anticoagulant therapy.


Subject(s)
Anticoagulants/adverse effects , Hemorrhage/chemically induced , Hemorrhage/prevention & control , Motor Activity , Venous Thromboembolism/drug therapy , Age Factors , Aged , Aged, 80 and over , Female , Hemorrhage/blood , Hemorrhage/diagnosis , Hemorrhage/mortality , Humans , Incidence , Male , Prospective Studies , Protective Factors , Risk Assessment , Risk Factors , Switzerland/epidemiology , Time Factors , Treatment Outcome , Venous Thromboembolism/blood , Venous Thromboembolism/diagnosis
8.
J Thromb Haemost ; 11(3): 435-43, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23279158

ABSTRACT

BACKGROUND: The Outpatient Bleeding Risk Index (OBRI) and the Kuijer, RIETE and Kearon scores are clinical prognostic scores for bleeding in patients receiving oral anticoagulants for venous thromboembolism (VTE). We prospectively compared the performance of these scores in elderly patients with VTE. METHODS: In a prospective multicenter Swiss cohort study, we studied 663 patients aged ≥ 65 years with acute VTE. The outcome was a first major bleeding at 90 days. We classified patients into three categories of bleeding risk (low, intermediate and high) according to each score and dichotomized patients as high vs. low or intermediate risk. We calculated the area under the receiver-operating characteristic (ROC) curve, positive predictive values and likelihood ratios for each score. RESULTS: Overall, 28 out of 663 patients (4.2%, 95% confidence interval [CI] 2.8-6.0%) had a first major bleeding within 90 days. According to different scores, the rate of major bleeding varied from 1.9% to 2.1% in low-risk, from 4.2% to 5.0% in intermediate-risk and from 3.1% to 6.6% in high-risk patients. The discriminative power of the scores was poor to moderate, with areas under the ROC curve ranging from 0.49 to 0.60 (P = 0.21). The positive predictive values and positive likelihood ratios were low and varied from 3.1% to 6.6% and from 0.72 to 1.59, respectively. CONCLUSION: In elderly patients with VTE, existing bleeding risk scores do not have sufficient accuracy and power to discriminate between patients with VTE who are at a high risk of short-term major bleeding and those who are not.


Subject(s)
Anticoagulants/adverse effects , Decision Support Techniques , Hemorrhage/chemically induced , Venous Thromboembolism/drug therapy , Acute Disease , Age Factors , Aged , Aged, 80 and over , Chi-Square Distribution , Discriminant Analysis , Drug Monitoring/methods , Female , Humans , International Normalized Ratio , Kaplan-Meier Estimate , Likelihood Functions , Logistic Models , Male , Predictive Value of Tests , Prospective Studies , ROC Curve , Reproducibility of Results , Risk Assessment , Risk Factors , Switzerland , Time Factors , Treatment Outcome
9.
J Thromb Haemost ; 10(11): 2270-6, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22985129

ABSTRACT

BACKGROUND: The Geneva Prognostic Score (GPS), the Pulmonary Embolism Severity Index (PESI) and its simplified version (sPESI) are well-known clinical prognostic scores for a pulmonary embolism (PE). OBJECTIVES: To compare the prognostic performance of these scores in elderly patients with a PE. PATIENTS AND METHODS: In a multicenter Swiss cohort of elderly patients with venous thromboembolism, we prospectively studied 449 patients aged ≥ 65 years with a symptomatic PE. The outcome was 30-day overall mortality. We dichotomized patients as low vs. higher risk in all three scores using the following thresholds: GPS scores ≤ 2 vs. > 2, PESI risk classes I-II vs. III-V and sPESI scores 0 vs. ≥ 1. We compared 30-day mortality in low- vs. higher-risk patients and the areas under the receiver-operating characteristic curve (ROC). RESULTS: Overall, 3.8% of patients (17/449) died within 30 days. The GPS classified a greater proportion of patients as low risk (92% [413/449]) than the PESI (36.3% [163/449]) and the sPESI (39.6% [178/449]) (P < 0.001 for each comparison). Low-risk patients based on the sPESI had a mortality of 0% (95% confidence interval [CI] 0-2.1%) compared with 0.6% (95% CI 0-3.4%) for low-risk patients based on the PESI and 3.4% (95% CI 1.9-5.6%) for low-risk patients based on the GPS. The areas under the ROC curves were 0.77 (95% CI 0.72-0.81), 0.76 (95% CI 0.72-0.80) and 0.71 (95% CI 0.66-0.75), respectively (P = 0.47). CONCLUSIONS: In this cohort of elderly patients with PE, the GPS identified a higher proportion of patients as low risk but the PESI and sPESI were more accurate in predicting mortality.


Subject(s)
Pulmonary Embolism/diagnosis , Pulmonary Embolism/mortality , Aged , Aged, 80 and over , Algorithms , Cohort Studies , Female , Hemodynamics , Humans , Male , Predictive Value of Tests , Prognosis , Prospective Studies , Pulmonary Embolism/pathology , ROC Curve , Risk , Severity of Illness Index , Switzerland , Treatment Outcome
10.
Thromb Res ; 129(4): 492-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21840043

ABSTRACT

INTRODUCTION: Rivaroxaban (RXA) is licensed for prophylaxis of venous thromboembolism after major orthopaedic surgery of the lower limbs. Currently, no test to quantify RXA in plasma has been validated in an inter-laboratory setting. Our study had three aims: to assess i) the feasibility of RXA quantification with a commercial anti-FXa assay, ii) its accuracy and precision in an inter-laboratory setting, and iii) the influence of 10mg of RXA on routine coagulation tests. METHODS: The same chromogenic anti-FXa assay (Hyphen BioMed) was used in all participating laboratories. RXA calibrators and sets of blinded probes (aim ii.) were prepared in vitro by spiking normal plasma. The precise RXA content was assessed by high-pressure liquid chromatography-tandem mass spectrometry. For ex-vivo studies (aim iii), plasma samples from 20 healthy volunteers taken before and 2 - 3hours after ingestion of 10mg of RXA were analyzed by participating laboratories. RESULTS: RXA can be assayed chromogenically. Among the participating laboratories, the mean accuracy and the mean coefficient of variation for precision of RXA quantification were 7.0% and 8.8%, respectively. Mean RXA concentration was 114±43µg/L .RXA significantly altered prothrombin time, activated partial thromboplastin time, factor analysis for intrinsic and extrinsic factors. Determinations of thrombin time, fibrinogen, FXIII and D-Dimer levels were not affected. CONCLUSIONS: RXA plasma levels can be quantified accurately and precisely by a chromogenic anti-FXa assay on different coagulometers in different laboratories. Ingestion of 10mg RXA results in significant alterations of both PT- and aPTT-based coagulation assays.


Subject(s)
Artifacts , Blood Coagulation Tests/methods , Drug Monitoring/methods , Factor Xa Inhibitors , Morpholines/blood , Thiophenes/blood , Adult , Anticoagulants/blood , Humans , Male , Reproducibility of Results , Rivaroxaban , Sensitivity and Specificity , Switzerland
12.
Rev Med Suisse ; 7(292): 905-10, 2011 Apr 27.
Article in French | MEDLINE | ID: mdl-21674894

ABSTRACT

Controversies regarding the pathogenesis of cardiovascular diseases in HIV patients Since the introduction of HAART (Highly active anti-retroviral therapy), the incidence of cardiovascular events has risen in patients infected with HIV. This development is mainly due to the increased survival in these patients. Nonetheless, the pathogenic effects of HIV on the principal components of haemostasis (endothelium, platelets and the clotting cascade) are the subject of numerous ongoing research studies, and are becoming an argument for starting HAART or for modifying the components of an established therapy. The aim of this article is to raise clinician awareness regarding the issue of cardiovascular disease in the HIV-infected patient.


Subject(s)
Cardiovascular Diseases/physiopathology , HIV Infections/physiopathology , Endothelium, Vascular/physiopathology , Humans
13.
J Thromb Haemost ; 8(8): 1797-808, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20546121

ABSTRACT

BACKGROUND: Interaction of murine Gas6 with the platelet Gas6 receptors Tyro3, Axl and Mer (TAM) plays an important role in arterial thrombus formation. However, a role for Gas6 in human platelet activation has been questioned. OBJECTIVE: To determine the role of Gas6 in human and murine platelet activation and thrombus formation. METHODS AND RESULTS: Gas6 levels appeared to be 20-fold higher in human plasma than in platelets, suggesting a predominant role of plasma-derived Gas6. Human Gas6 synergizes with ADP-P2Y(12) by enhancing and prolonging the phosphorylation of Akt. Removal of Gas6 from plasma impaired ADP-induced platelet aggregation. Under flow conditions, absence of human Gas6 provoked gradual platelet disaggregation and integrin α(IIb) ß(3) inactivation. Recombinant human Gas6 reversed the effects of Gas6 removal. In mouse blood, deficiency in Gas6 or in one of the TAM receptors led to reduced thrombus formation and increased disaggregation, which was completely antagonized by external ADP. In contrast, collagen-induced platelet responses were unchanged by the absence of Gas6 in both human and mouse systems. CONCLUSIONS: The ADP-P2Y(12) and Gas6-TAM activation pathways synergize to achieve persistent α(IIb) ß(3) activation and platelet aggregation. We postulate a model of thrombus stabilization in which plasma Gas6, by signaling via the TAM receptors, extends and enhances the platelet-stabilizing effect of autocrine ADP, particularly when secretion becomes limited.


Subject(s)
Intercellular Signaling Peptides and Proteins/metabolism , Platelet Activation , Proto-Oncogene Proteins/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Thrombosis/metabolism , Animals , Humans , Mice , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Recombinant Proteins/chemistry , Signal Transduction , Thrombosis/pathology , c-Mer Tyrosine Kinase , Axl Receptor Tyrosine Kinase
17.
J Eur Acad Dermatol Venereol ; 20(3): 327-30, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16503898

ABSTRACT

Coumarins and heparins are commonly used for temporary or long-term anticoagulation. These molecules have potentially devastating side-effects, including widespread skin necrosis. We report the case of an elderly patient under oral anticoagulation with coumarins, who developed widespread necrotic cutaneous lesions upon introduction of intravenous and subcutaneous unfractionated heparin administration for a surgical procedure. Laboratory investigations revealed the presence of circulating antibodies directed against heparin-platelet factor 4. The lesions slowly resolved after withdrawal of heparin, whereas oral coumarin was re-introduced without complications. This case illustrates the rare occurrence of skin necrosis as a result of unfractionated heparin in a patient under chronic coumarin medication. Recognition of this rare complication and appropriate laboratory testing is mandatory for prompt institution of alternative anticoagulant therapies.


Subject(s)
Anticoagulants/adverse effects , Heparin/adverse effects , Skin/pathology , Aged , Anticoagulants/administration & dosage , Arm/pathology , Cardiomyopathies/drug therapy , Colonic Neoplasms/surgery , Coumarins/administration & dosage , Diagnosis, Differential , Drug Administration Schedule , Heparin/administration & dosage , Humans , Infusions, Intravenous , Injections, Subcutaneous , Male , Necrosis/chemically induced , Necrosis/diagnosis , Necrosis/pathology , Postoperative Complications/chemically induced , Postoperative Complications/diagnosis , Postoperative Complications/pathology
19.
Nat Med ; 7(2): 215-21, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11175853

ABSTRACT

The growth arrest-specific gene 6 product (Gas6) is a secreted protein related to the anticoagulant protein S but its role in hemostasis is unknown. Here we show that inactivation of the Gas6 gene prevented venous and arterial thrombosis in mice, and protected against fatal collagen/epinephrine-induced thrombo embolism. Gas6-/- mice did not, however, suffer spontaneous bleeding and had normal bleeding after tail clipping. In addition, we found that Gas6 antibodies inhibited platelet aggregation in vitro and protected mice against fatal thrombo embolism without causing bleeding in vivo. Gas6 amplified platelet aggregation and secretion in response to known agonists. Platelet dysfunction in Gas6-/- mice resembled that of patients with platelet signaling transduction defects. Thus, Gas6 is a platelet-response amplifier that plays a significant role in thrombosis. These findings warrant further evaluation of the possible therapeutic use of Gas6 inhibition for prevention of thrombosis.


Subject(s)
Blood Platelets/physiology , Intercellular Signaling Peptides and Proteins , Proteins/physiology , Thrombosis/prevention & control , Animals , Blood Platelets/metabolism , Cell Line , Disease Models, Animal , Female , Gene Expression , Hemostasis , Humans , Male , Mice , Mice, Knockout , Phenotype , Platelet Aggregation , Proteins/genetics , Proteins/immunology , Proteins/pharmacology , Receptors, Cell Surface/genetics , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Thrombosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...